The incidence of asthma is increasing throughout the world, which presents both public health and economic concerns. It is widely recognized that in some adult patients with asthma, aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX)-1 exacerbate the condition. This is a distinct clinical syndrome called aspirin-induced asthma (AIA). The disease develops according to a characteristic pattern of symptoms. Persistent eosinophilic rhinosinusitis precedes development of nasal polyposis, aspirin hypersensitivity, and asthma. There is no in vitro test, and diagnosis can only be established by provocation tests with aspirin. At the biochemical level, AIA is characterized by a chronic overproduction of cysteinyl leukotrienes. The key enzyme, leukotriene C 4 synthase, is overexpressed in bronchi, and its messenger RNA is upregulated in peripheral blood eosinophils. This can be partly related to the genetic polymorphism of the enzyme. The disease runs a protracted course, even if COX-1 inhibitors are avoided. The course of AIA is often severe, and at least half of the patients need systemic corticosteroids to control their asthma. To prevent life-threatening reactions, patients with AIA should avoid aspirin and other analgesics that inhibit COX-1. The incidence of cross-sensitivity to paracetamol in AIA patients is low and, when a reaction does occur, the symptoms experienced are shorter and milder than if the reactions were evoked by an NSAID. Rapidly growing evidence indicates that highly specific COX-2 inhibitors, known as coxibs, are well tolerated and can be safely used by AIA patients.
INTRODUCTION
Most people tolerate aspirin and nonsteroidal antiinflammatory drugs (NSAIDs) well, if used for short periods. However, some asthmatics are an exception. In these patients, aspirin and NSAIDs may exacerbate asthma and precipitate life-threatening reactions. Most asthmatics take analgesics at some time or another to treat a variety of ailments, but many of them do not realize the potential risks that such medicines may pose. As the number of people with asthma worldwide continues to rise, recognizing that aspirin and other NSAIDs can cause bronchoconstriction in certain asthmatics will become increasingly important. Attempts to classify allergic and pseudoallergic reactions to aspirin and other anti-inflammatory and analgesic drugs have met with considerable difficulty. A proposal for classification has been recently published. 1 The mechanisms involved may vary, but in large part, they are related to pharmacologic action of NSAIDs, 2 ie, inhibition of cyclooxygenase (COX). The first part of this review discusses the metabolic events mediated by COX and their pharmacologic inhibition. We then discuss the clinical syndrome of aspirininduced asthma (AIA), also called analgesic-induced asthma or NSAID-exacerbated asthma. and thromboxane A 2 . These autocoidal lipid mediators activate specific G-coupled cell-membrane receptors. In the airways, they cause bronchoconstriction (prostaglandins D 2 , F 2 , and thromboxane A 2 ), vasodilatation (prostacyclin), bronchodilatation, and various immunomodulatory effects (both prostaglandin E 2 ). 5 COX may also be involved in synthesis of isoprostanes, which are isomers of prostaglandins formed by free radical oxygenation of arachidonic acid. Isoprostanes are of interest as markers of oxidant injury and as physiologic analogs of prostaglandins.
It is now recognized that there are two related but distinct genes that code for prostaglandin G/H synthase, termed COX-1 and COX-2. COX-1, expressed constitutively in most tissues, is thought to release prostaglandins involved in housekeeping functions, such as the maintenance of the gastrointestinal tract and vascular homeostasis. COX-2 is undetectable in most tissues. It can be upregulated by bacterial lipopolysaccharides, cytokines, growth factors, and tumor promoters, suggesting its relevance to inflammation and cancer. Although the catalytic activities and tertiary structures of COX-1 and COX-2 are remarkably similar, 4 COX-2 has a broader specificity for substrates because the hydrophobic channel leading to the active site of this enzyme is more accommodating. However, distinguishing COX-1 as a constitutive enzyme and COX-2 as an inducible enzyme responsible for the formation of prostanoids in disease is an oversimplification of the biologic reality. 6 The involvement of prostanoid mediators has been studied extensively using gene-targeting strategies in mice with COX-1 or COX-2 knockouts (ie, gene deleted). The animals deficient in COX activity had normal lungs. 7 Ovoalbumin-sensitized mice, deficient in either COX enzyme, had increased bronchoalveolar fluid eosinophilia, accompanied by macrophage and lymphocyte influx after ovalbumin challenge. COX-1 deficiency led to a more severe phenotype distinguished by a doubling in the number of eosinophils and activation of macrophages in bronchoalveolar fluid and by a hyperresponsiveness of the airways to intravenous metacholine challenge. These differences also extended to metabolism of leukotrienes. Increased leukotriene B 4 and cysteinyl leukotrienes (cys-LTs) were observed only in those mice deficient in COX-1. These differences were significant in comparison with other groups studied: sensitized COX-2deficient, sensitized only, and nontreated mice. The observations in these knockout mice seem to corroborate the actions of the specific COX inhibitors on airways in patients.
Aspirin and other NSAIDs inhibit both COX-1 and COX-2. They differ in inhibitory potency, and their pharmacokinetic and pharmacodynamic properties determine their action in the individual patient. Depression of prostaglandin synthesis is thought to account for both therapeutic and adverse effects associated with the administration of NSAIDs. 2 Inhibition of COX-2 has been implicated in ameliorating inflammation and pain, whereas the inhibition of COX-1 has been related to adverse effects in the gastrointestinal tract, such as dyspepsia and abdominal pain, and, less frequently, gastric and duodenal perforation and bleeding. Based on these premises, selective COX-2 inhibitors known as coxibs have been developed. Large clinical trials 8, 9 performed with the first coxibs (rofecoxib and celecoxib) showed that they are as effective as classic NSAIDs but cause significantly fewer gastrointestinal adverse events. Possible clinical relevance of cardiovascular actions of coxibs 10 has been a matter of recent debate. [11] [12] [13] [14] AIA: DEFINITION OF THE SYNDROME AIA is a distinct clinical syndrome characterized by precipitation of rhinitis and asthma attacks by aspirin and most other NSAIDs. 15 Asthma runs a protracted course for years, despite the avoidance of aspirin and cross-reacting drugs, and systemic corticosteroids are often necessary to control the symptoms. Recent interest in AIA has been stirred by the finding of alterations in arachidonate metabolic pathways, leading to cysteinyl leukotriene overproduction. The availability of antileukotriene drugs has amplified the attention paid to the syndrome.
PREVALENCE OF AIA
There is variation in the rates of prevalence reported in the literature, and this seems to be because of differences in the methodology used and the patient populations evaluated. Based on patients' history alone, the incidence of aspirin hypersensitivity in adult asthmatics is 3% to 5%, but this percentage doubles or triples when the adult asthmatic patient is challenged with aspirin. 16 Aspirin sensitivity is also associated with persistent airflow limitation in severe asthma (which is not related to prior aspirin use). 17 In a recent study, 18 16% of British patients with continuous asthma were found to suffer from aspirin intolerance. In a population-based random sample of 4300 adult women and men of southern Finland, 19 the prevalence of aspirin intolerance causing a shortness of breath or attacks of asthma was 1.2%, and it was higher in patients with doctor-diagnosed asthma than without (8.8% vs 0.8%). In a further study, two populations of asthmatics and a group of randomly selected individuals were surveyed by questionnaire to establish the prevalence of AIA in the metropolitan area of Perth, western Australia. According to the questionnaire results, the prevalence of respiratory symptoms triggered by aspirin-NSAID use was found to be 10% to 11% among asthmatics and 2.5% among nonasthmatics. 20 Regardless of its prevalence, AIA is widely underdiagnosed in the asthmatic population. The reasons why it remains underdiagnosed may include the deliberate avoidance of NSAIDs by asthmatic patients who are aware of adverse reactions or a lack of recognition of mild NSAID-induced reactions by patients because of their delayed onset of action. 21 In a recent study, 22 15% of asthmatics were unaware of aspirin intolerance before having aspirin provocation tests. This indicates that underdiagnosis of aspirin sensitivity may be because of the lack of routine aspirin challenge testing of asthmatic patients who do not report a positive history of aspirin sensitivity. Low awareness among health care professionals as well as patients is an additional factor.
CLINICAL PRESENTATION
The natural history and clinical characteristics of AIA were recently described based on a study of 500 patients coming from ten European countries, with diagnosis confirmed by aspirin provocation tests. 22 AIA developed according to a characteristic sequence of symptoms: persistent rhinitis appeared at an average age of 30 years, followed by asthma, aspirin intolerance, and nasal polyposis. In women, who outnumbered men by 2.3:1, the onset of symptoms occurred significantly earlier, and the disease was more progressive and severe than in men. Blood eosinophil counts were raised, and eosinophils were present in bronchial mucosa and airways.
Overexpression of interleukin-5 present in the airways was not reflected in the blood of patients. 23 Atopy was recorded in a third of the patients studied, and a similar percentage was reported from Poland, 24 Turkey, 25, 26 and Italy. 27 AIA developed in a similar way all over Europe, suggesting a common underlying principle.
Rhinitis, the first symptom of AIA, was usually related to a flu-like infection and was characterized by a watery discharge from the nose. It was perennial, difficult to treat, and associated with sinusitis. It led to loss of smell and to nasal polyposis in about twothirds of patients.
Bronchial asthma and hypersensitivity to aspirin usually manifested within 1 year to 5 years after the onset of rhinitis. 21, 22 After ingestion of aspirin or an NSAID, an acute asthma attack develops within 3 hours, usually accompanied by profuse rhinorrhea, conjunctival injection, and sometimes a scarlet flushing of the head and neck and periorbital edema.
Aspirin and other NSAIDs can precipitate life-threatening attacks of asthma. 28 In a French survey, 29 25% of asthmatics requiring emergency mechanical ventilation were found to have AIA. Rarely, in patients who produce extremely high amounts of cys-LTs, myocardial ischemia may develop. 30 
DIAGNOSIS
The presence of AIA should be suspected in cases presenting a history of attacks of dyspnea precipitated by aspirin and other NSAIDs, chronic nasal congestion and watery rhinorrhea, nasal polyposis, or severe attack of asthma requiring hospitalization in an intensive care unit. [31] [32] [33] Diagnosis can only be established with certainty by provocation (challenge) tests with increasing doses of aspirin. 34 There are four types of provocation tests, depending on the route of aspirin administration: oral, bronchial (inhaled), nasal (drops), and intravenous, although the last is rarely used. 35 Oral challenge tests are most commonly performed; in most patients, threshold doses evoke positive reactions after ingesting 30 mg to 150 mg aspirin (average, 75 mg). In inhalation tests, aerosols of L-lysine acetylsalicylic acid are administered 36 and can be completed in 4 hours, but reactions are usually restricted to the lower respiratory tract. Both oral and bronchial tests have similar specificity, but the oral test has somewhat higher sensitivity. 35 Nasal provocation testing is an attractive research model and can also be used as a diagnostic procedure in outpatients; its value, however, is limited by reduced sensitivity when compared with oral or inhalation provocation testing. 37 All these tests should always be preceded by placebo challenge the day before proper test to exclude the variability of bronchial responsiveness. In recent years, the provocation tests have been accompanied by measurement of urinary leukotriene E 4 . [38] [39] [40] Severity of respiratory reactions during oral aspirin challenges was reported to be associated with the degree of elevation of baseline leukotriene E 4 synthesis. 41 There is no in vitro test for the diagnosis of AIA. The preliminary optimistic reports [42] [43] [44] on the diagnostic value of measurement of cys-LTs released by peripheral blood leukocytes after ex vivo stimulation were not confirmed in later studies. [45] [46] [47] 
INVOLVEMENT OF EICOSANOIDS IN AIA PATHOGENESIS
Over 25 years ago, it was proposed that asthma attacks precipitated by aspirin are not caused by an al-lergic reaction but result from inhibition of COX by aspirin-like drugs in the airways of the sensitive patients. 48 Confirmation of this proposition by various groups 49, 50 led to the formulation of the COX theory. 51 Recent clinical studies [52] [53] [54] [55] indicate that it is inhibition of COX-1, and not COX-2, that precipitates asthma attacks. These findings corroborate observations on diminished COX-2 expression and activity in nasal polyps from AIA patients, [56] [57] [58] and they support the concept of the prostaglandin E 2 brake 46,59-62 as an important factor in response to NSAIDs. Prostaglandin E 2 , a major arachidonate product in the airways, is a bronchodilator; it suppresses leukotriene biosynythesis, as well as several immunologic functions. In AIA, the pharmacologic action of COX-1 inhibitors would enhance depletion of this protective prostaglandin, which is downregulated because of COX-2 deficiency. This concept still awaits confirmation, possibly through a study of the patient's airway cell cultures.
Over the last few years, cys-LTs have emerged as the main mediators of AIA (Fig. 2) . Biosynthesis of cys-LTs is upregulated in AIA. 39, 63 The key enzyme, leukotriene C 4 synthase (LTC 4 S), is overexpressed in bronchial mucosa. 64 Circulating blood eosinophils of AIA patients carry more messenger RNA for this enzyme. 65 This activation of LTC 4 S gene transcription can only partly be explained by genetic variability of the gene's promoter. 66 Allelic variant −444 C associates with AIA and is a marker of the severe, steroiddependent phenotype of the disease. 65 Although a replication study did not confirm an allelic association with aspirin hypersensitivity, a deviation from Hardy-Weinberg genetic equilibrium was observed in AIA patients from the United States. 67 Such departure of genotype frequencies usually reflects association with the disease allele. 68 Cys-LTs are important proinflammatory effectors of AIA. 39, 50 Molecular determinants limiting expression of LTC 4 S to restricted cell types were studied at the transcriptional level. Basic expression of the enzyme depends on ubiquitous Sp1 and Sp3 transcription factors. 69 An enhancer element interacting with a Kruppel-like protein of the zinc-finger family seems to convey cell-type specificity. Variation of the gene's promoter can result in an additional enhancer element, which possibly increases its expression in relation to the cell cycle. 70 In a preliminary study, capacity for activated accumulation of leukotriene C 4 was increased in severe asthmatics who inherited an allelic variant of the LTC 4 S promoter. 71 AIA patients were reported to be sensitive to inhaled cys-LT E 4 72 but not C 4 or D 4 . 73, 74 Within the last year, the DNA sequences of both cys-LT 1 75,76 and cys-LT 2 77,78 receptors have been described and their ligand-binding properties studied. Both receptors have quite similar agonist characteristics, having greater affinity for leukotrienes D 4 and C 4 than for leukotriene E 4 . However, only cys-LT 1 is selectively blocked by leukotriene-receptor antagonists montelukast, zafirlukast, and pranlukast, drugs that have been recently introduced for the treatment of asthma. In AIA patients, cys-LT receptors await characterization, which could explain their high sensitivity to leukotriene E 4 .
One reason for increased pharmacodynamic action of cys-LTs in AIA patients might be the diminished capacity of lipoxin biosynthesis. 79 Lipoxins, antiinflammatory derivatives of arachidonic acid, are products of lipoxygenation. They are generated mainly by transcellular metabolism and behave as functional antagonists of leukotrienes. 80 Deficiency of 15-epi-lipoxins, especially of the active isomers, might be a factor contributing to the self-perpetuating and protracted clinical course of AIA. 81 At the cellular level, besides eosinophils, which are the richest source of cys-LTs, mast cells may also be involved. [82] [83] [84] [85] 
PREVENTION
To prevent life-threatening reactions, patients with AIA should avoid aspirin, all products containing aspirin, and other analgesics that inhibit COX-1. Thus, the education of physicians, pharmacists, and patients is extremely important. The patient should receive a list of drugs that are contraindicated, 33 preferably with both generic and trade names.
Patients with AIA can safely receive sodium salicylate, salicylamide, choline magnesium trisalicylate, benzydamine, chloroquine, azapropazone, and dex-tropropoxyphene. These drugs are weak COX-2 inhibitors. Unfortunately, they are poor analgesics and have only mild anti-inflammatory effects. Nimesulide and meloxicam, drugs known to inhibit COX-2 more than COX-1, induced mild bronchial obstructions, although only at high doses. 26, [86] [87] [88] [89] The evidence is rapidly growing that coxibs such as rofecoxib and celecoxib, which are selective COX-2 inhibitors, are well tolerated by AIA patients. [52] [53] [54] [55] In a double-blind, controlled study of AIA patients, 53 they do not seem to interfere with eicosanoid metabolism; rofecoxib, unlike aspirin, precipitated neither clinical symptoms nor raised cys-LT production.
Paracetamol deserves a special note not only because of its common therapeutic use but also because of recent debate over its relationship to the development of asthma. It has been claimed that the frequent use of paracetamol contributes to asthma morbidity by depleting glutathione in the upper and lower airways. 90 This is supposed to shift the oxidant-antioxidant balance in favor of oxidative stress with a consequent increase of inflammation and upregulation of NF-B. These effects were said to account for the observed association between consumption of paracetamol and the prevalence of asthma symptoms in adults in London 90 and also the association between the sales of paracetamol in different countries and the incidence of atopic diseases, including asthma. 91 The effects of normal therapeutic doses of paracetamol on lung glutathione in man are unknown, but a single, large dose of 2 g produced only a minor transient fall in plasma glutathione in healthy volunteers. 92 In 40 children with fever, aged 9 months to 11 years, administration of paracetamol in doses 43 to 54 mg/kg per day for an average of 3 days to 5 days was associated with an increased concentration of reduced glutathione in erythrocytes. 93 It seems unlikely that therapeutic doses of paracetamol could reduce glutathione concentrations to the extent that oxidative damage occurred in the lung or airways. If paracetamol indeed caused or aggravated asthma, then bronchoconstriction should be a common complication of paracetamol poisoning, but this has not been observed, except in patients who are sensitive to Nacetylcysteine 94, 95 , which is commonly used as an antidote for paracetamol poisoning. Similarly, asthma should be common in patients with arthritis and migraine who take paracetamol regularly. Such associations have never been described. Finally, patients with glutathione synthase deficiency should have asthma, but this is not the case. Thus, the glutathione hypothesis for paracetamol-induced asthma at therapeutic doses of paracetamol remains biologically implausible.
Paracetamol is a weak inhibitor of COX-1 and COX-2, which displays some selectivity toward COX enzymes from different organs. 96 The activity of paracetamol in vitro depends on the addition of cofactors. These observations led to speculation that paracetamol may be acting on hypothetic COX-2 catalytic variants or on a COX-3 enzyme 96 ; however, this area is still being investigated. Paracetamol's low inhibitory potency for COX enzymes explains its bronchospastic properties observed occasionally in AIA patients. [97] [98] [99] [100] [101] [102] [103] Most AIA patients can safely take paracetamol at doses of 1000 mg or less. However, at doses Ն1000 mg, paracetamol can induce detectable bronchospastic reactions in as many as 30% of AIA patients. 103, 104 However, these data were identified in patients that were exquisitely or highly sensitive to aspirin. Such reactions were milder than those induced by aspirin in two ways. First, the duration of bronchospasm was significantly shorter for paracetamol, and second, significantly fewer bronchodilator treatments were required to reverse bronchospasm. Paracetamolinduced asthma seems to be more common in patients who are exquisitely sensitive to low-provoking doses of aspirin. Because AIA remains largely underdiagnosed, asthmatics (not AIA patients, per se) who are self-medicating, buying analgesics over-the-counter, and are not under regular doctor's supervision might be advised about a rare possibility (estimated to be 1% or less) of exacerbation of their asthma by paracetamol. In conclusion, in AIA patients, it is generally safer not to exceed a dose of 1000 mg paracetamol, and when starting the therapy, it is wise to administer small doses of the drug and monitor the patient for 3 hours. This contrasts, for example, with dipyrone, which must not be taken by AIA patients because it invariably leads to severe bronchoconstructive response. 105 It should be noted that a very rare, purely allergic, hypersensitivity to paracetamol has been described in the absence of aspirin intolerance, and the mechanism of this clinical complication is different to the AIA cross-sensitivity with paracetamol as described previously. 106, 107 TREATMENT Patients with AIA whose sinusitis is in remission may have mild asthma. 33 However, most patients have moderate or severe persistent asthma. In Europe, about half of AIA patients require chronic treatment with systemic (oral) corticosteroids to control the disease. 22 Chronic aspirin desensitization can be induced and maintained by administering increasing doses of aspirin over a period of 2 days to 5 days, reaching a dose of 600 mg to 1200 mg, which then has to be given every day. Such an approach often leads to clinical improvement of the symptoms, especially in the nose. 33, 108 It can delay recurrence of nasal polyp formation for a few years. Chronic treatment with aspirin endonasal inhalation at the dose of 4 mg daily for 6 days per week attenuated nasal symptoms and prevented regrowth of nasal polyps, 109 possibly inhibiting fibroblast activity. 110 Few clinical trials with antileukotriene drugs have been performed in AIA patients. Two trials showed good therapeutic efficacy of chronic treatment with a 5-LO inhibitor 111 or a cys-LT receptor antagonist. 112 In very rare cases, treatment of asthma patients with cys-LT receptor antagonists is associated with development of Churg-Strauss syndrome, 113 but this may be entirely because of the reduction of the corticosteroid dose. In an acute study, 114 pretreatment of 16 AIA patients with pranlukast, a leukotriene receptor antagonist, significantly attenuated bronchospastic reactions precipitated by a COX-inhibitor (sulpiryne) or metacholine, without affecting urinary excretion of leukotriene E 4 . However, it was reported that some individual AIA patients developed bronchospasm after taking a NSAID known to inhibit COX despite being on chronic treatment with zafirlukast 115 or montelukast. 116 Surprisingly, aspirin-tolerant and aspirinintolerant patients with asthma do not seem to differ in clinical response to montelukast. 18, 117, 118 Perhaps tachyphylaxis, downregulation of cys-LT receptors, or both occur in AIA patients because of leukotriene overproduction. Urinary leukotriene E 4 is a poor predictor of clinical response, probably because only 10% to 15% of cys-LTs produced in the body are excreted by the kidneys. Preliminary observations 71, 117, 119 indicate that response to leukotriene receptor antagonists is better in asthmatic carriers of LTC 4 S allele C than in noncarriers.
Inhaled prostaglandins of the E series prevent aspirin-precipitated bronchoconstriction in aspirinsensitive asthmatics. 120, 121 However, misoprostol, a stable analogue of prostaglandin E 1 , taken orally at a daily dose of 800g or 1600 g, did not improve asthma control in 17 subjects with AIA. 122 Symptoms, blood eosinophils, serum eosinophilic cationic protein, sputum eosinophils, and sputum eosinophilic cationic protein decreased significantly in 14 aspirin-intolerant asthmatics after 8 weeks' treatment with a daily dose of 150 mg roxitromycin. 123 Values of PC 20 -sulpiryne (the dose of the drug causing a 20% fall in forced expiratory volume in 1 sec.) did not improve, and the therapy had no effect on the urinary excretion of leukotriene E 4 .
An innovative approach was taken by Yoshida and colleagues 124 based on a viral hypothesis of AIA origin. 125 They showed that pretreatment with acyclovir, an inhibitor of the DNA polymerase of the herpes virus, prevented analgesic (sulipryne)-precipitated bronchoconstriction and rise in urinary leukotriene E 4 in 16 AIA patients. Acyclovir, at a dose of 400 mg, was given only 80 minutes before the provocation test. This research supports earlier, preliminary observations from Japan 126, 127 and warrants further study.
Rhinosinusitis in AIA is often a serious therapeutic problem. 128 Nasal decongestants and antihistamines give limited relief, but topical steroids seem to be effective. [129] [130] [131] Hosemann 132 reviewed the rhinologic outcome of surgical treatment of nasal polyps of patients suffering from analgesic intolerance. The subjective success rate for pansinus surgery was about 80%. However, many patients continued to exhibit nasal symptoms, such as anosmia. The subjective results were not in agreement with postoperative endoscopic findings. Recurrence of nasal polyposis was observed in 10% to 40% cases. Thus, AIA patients should receive an additional treatment including topical or systemic corticosteroids, aspirin desensitization, and possibly antileukotriene drugs. Optically aided endonasal techniques represent the gold standard for surgery. Simple polypectomy alone is not encouraged, and more extensive procedures should be considered.
In summary, as the prevalence of asthma continues to rise, self-medication in the asthmatic population will become an increasing public health concern, requiring education of health care professionals as well as patients.
Appropriate analgesic use is an important practical issue because a number of analgesics can influence the course of asthma, lead to its exacerbation, or even cause dramatic attacks. Over 150 million people are currently diagnosed with asthma worldwide, 133 and a significant proportion of these people will be at risk for developing AIA. Because aspirin intolerance can take many years to develop and may occur in patients who have previously taken aspirin with no adverse effects, many patients with AIA may be unaware that aspirin and other NSAIDs can be related to their asthma attacks. This underlines the scale of the problem and highlights the need both for health care professionals to exercise caution when recommending suitable analgesics and for asthmatics to be aware of the risks when selecting an analgesic OTC.
To prevent life-threatening reactions, patients with AIA should avoid aspirin and other analgesics that inhibit COX-1. The incidence of cross-sensitivity to paracetamol in AIA patients is low, and when a reaction does occur, the symptoms experienced are shorter and milder than if the reactions were evoked by an NSAID. Rapidly growing evidence indicates that highly specific COX-2 inhibitors, known as coxibs, are well tolerated and can be safely used by AIA patients.
Studies on the mechanisms and treatment of AIA are ongoing and may bring new insight into the pathogenesis and management of bronchial asthma, leading to improved strategies for preventing the development of AIA.
